Overview

Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study

Status:
Completed
Trial end date:
2018-02-15
Target enrollment:
Participant gender:
Summary
This study aims to describe the patient population treated and the real-life patients' experiences with Xamiol®gel in the long term, up to 52 weeks management of body psoriasis vulgaris in Russia. The result will increase the knowledge on Xamiol®gel enabling dermatologists and patients to optimize its use in the long term management of psoriasis.
Details
Lead Sponsor:
LEO Pharma
Treatments:
Betamethasone
Betamethasone benzoate
Betamethasone sodium phosphate
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Calcipotriene